These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 25829086

  • 1. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
    Kwee RM, Marcus C, Sheikhbahaei S, Subramaniam RM.
    PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
    [Abstract] [Full Text] [Related]

  • 2. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S.
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PET/Computed Tomography and Patient Outcomes in Melanoma.
    Rohren EM.
    PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
    [Abstract] [Full Text] [Related]

  • 5. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
    Metser U, Rashidi F, Moshonov H, Wong R, Knox J, Guindi M, Darling G.
    Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
    [Abstract] [Full Text] [Related]

  • 6. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 7. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC, Pramesh CS, Karimundackal G, Jiwnani S, Agrawal A, Shah S, Kulkarni M, Laskar SG, Rangarajan V.
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [Abstract] [Full Text] [Related]

  • 12. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 13. Lung cancer.
    Akhurst T, MacManus M, Hicks RJ.
    PET Clin; 2015 Apr; 10(2):147-58. PubMed ID: 25829084
    [Abstract] [Full Text] [Related]

  • 14. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
    Li YL, Wu LM, Chen XX, Delproposto Z, Hu JN, Xu JR.
    J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
    [Abstract] [Full Text] [Related]

  • 15. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B, Schwenzer NF, Gatidis S, Koenigsrainer I, Koenigsrainer A, Beckert S, Mueller M, Claussen CD, Pfannenberg C.
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
    Cervino AR, Pomerri F, Alfieri R, Sileni VC, Castoro C, Galuppo S, Evangelista L.
    Nucl Med Commun; 2014 Feb; 35(2):160-8. PubMed ID: 24220054
    [Abstract] [Full Text] [Related]

  • 18. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
    Wray R, Solnes L, Mena E, Meoded A, Subramaniam RM.
    PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
    [Abstract] [Full Text] [Related]

  • 19. FDG PET/CT in the management of colorectal and anal cancers.
    Agarwal A, Marcus C, Xiao J, Nene P, Kachnic LA, Subramaniam RM.
    AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.